Cash Flow Statement
Growth Metrics

Anika Therapeutics (ANIK) Non-Current Deferred Tax Liability (2016 - 2023)

Anika Therapeutics has reported Non-Current Deferred Tax Liability over the past 14 years, most recently at $2.0 million for Q3 2023.

  • Quarterly Non-Current Deferred Tax Liability fell 71.25% to $2.0 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2023, down 71.25% year-over-year, with the annual reading at $6.4 million for FY2022, 36.63% down from the prior year.
  • Non-Current Deferred Tax Liability was $2.0 million for Q3 2023 at Anika Therapeutics, down from $3.2 million in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $16.0 million in Q1 2020 and troughed at $2.0 million in Q3 2023.
  • The 5-year median for Non-Current Deferred Tax Liability is $8.2 million (2022), against an average of $8.4 million.
  • Year-over-year, Non-Current Deferred Tax Liability skyrocketed 373.14% in 2020 and then plummeted 71.25% in 2023.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $4.3 million in 2019, then soared by 174.65% to $11.9 million in 2020, then dropped by 14.61% to $10.2 million in 2021, then tumbled by 36.63% to $6.4 million in 2022, then crashed by 69.62% to $2.0 million in 2023.
  • Per Business Quant, the three most recent readings for ANIK's Non-Current Deferred Tax Liability are $2.0 million (Q3 2023), $3.2 million (Q2 2023), and $4.1 million (Q1 2023).